Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. (SEPN) Form 4: An executive identified as SVP, Drug Discovery reported a sale of 3,501 shares of common stock on 11/10/2025, coded “S.” The weighted average sale price was $18.0586.
The filing notes sales occurred across a price range of $18.04 to $18.16. Following the transaction, the reporting person beneficially owns 92,911 shares, held directly.
According to the footnote, this figure includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on 10/31/2025 in transactions exempt under Rule 16b-3(c).
Septerna, Inc. reported a profitable Q3 2025 as collaboration revenue ramped and interest income increased. Revenue was $21,495 thousand for the three months ended September 30, 2025, up from $176 thousand a year ago, reflecting recognition under its Novo Nordisk collaboration. The company recorded net income of $8,173 thousand in Q3 2025, compared to a net loss of $20,523 thousand in Q3 2024. Results also included a $12,500 thousand gain on sale of a non‑financial asset tied to a Vertex milestone.
Liquidity strengthened with cash, cash equivalents and marketable securities of $561,600 thousand as of September 30, 2025. Deferred revenue was $182,250 thousand (current $61,603 thousand; non‑current $120,647 thousand) from the $195,000 thousand Novo upfront received in July 2025, of which $12,750 thousand was recognized year‑to‑date. R&D expense was $24,264 thousand and G&A was $7,117 thousand in Q3 2025. Shares outstanding were 44,774,192 as of November 4, 2025.
Septerna, Inc. (SEPN) filed an 8-K announcing results and business highlights for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 detailing the update.
The information under Item 2.02, including Exhibit 99.1, is being furnished, not deemed “filed” under the Exchange Act. Septerna’s common stock trades on the Nasdaq Global Market under the symbol SEPN.
Septerna, Inc. director Keith Michael Gottesdiener was granted a stock option to purchase 33,246 shares of common stock with an exercise price of $16.75. The option was issued on 09/25/2025, becomes exercisable in monthly installments equal to 1/36th of the shares beginning on that date (subject to continued service), and expires on 09/24/2035. Following the reported transaction, the reporting person beneficially owned 33,246 option shares, held directly. The Form 4 was signed via attorney-in-fact on 09/29/2025. No other securities or cash transactions are reported.
Septerna, Inc. (SEPN) director Keith Michael Gottesdiener filed an initial Form 3 disclosing his relationship to the issuer and stating no securities are beneficially owned. The filing lists his address at Septerna, Inc., identifies him as a director, and is signed by an attorney-in-fact on his behalf. The form reports the event date as 09/25/2025.
Septerna, Inc. furnished an 8-K disclosing a non-employee director compensation matter. The filing incorporates the company’s Non-Employee Director Compensation Policy by reference from the April 29, 2025 proxy statement and states that Dr. Gottesdiener will receive an additional annual cash retainer of $12,000 for serving as Chair of the R&D Committee, paid quarterly in arrears and prorated for partial quarters. The filing also notes a press release dated September 29, 2025 was furnished and the report is signed by CEO Jeffrey Finer, M.D., Ph.D.
Septerna, Inc. filed a current report to note that it has updated its corporate presentation for use in meetings with investors, analysts and others. The revised presentation, dated September 2025, is furnished as Exhibit 99.1 to this report and is incorporated by reference for informational purposes.
The company states that the materials provided under this item are being furnished rather than filed, meaning they are not subject to certain liability provisions of the Securities Exchange Act and are not automatically incorporated into other SEC filings unless specifically referenced.
Septerna, Inc. furnished an update on its drug development pipeline, reporting that it has begun dosing the first participants in a Phase 1 clinical trial of SEP-631. The press release describes SEP-631 as an oral small molecule MRGPRX2 negative allosteric modulator being studied for the treatment of mast cell-driven diseases, marking an early clinical step for this program. The communication is provided under Regulation FD as furnished information, not filed, and is attached as Exhibit 99.1.
Septerna, Inc. director and Senior Vice President, Biological Sciences, Uwe Klein reported multiple acquisitions of the issuer's common stock and stock options on 08/18/2025. He purchased options exercisable into 10,452, 4,935, and 7,621 shares at exercise prices of $2.76, $2.76, and $6.81 respectively, and those options underlie the reported common shares. The Form 4 shows 10,452, 4,935, and 7,621 shares were acquired at reported option prices of $2.76, $2.76, and $6.81, and following transactions Klein directly beneficially owns 23,008 shares. In addition, Klein discloses indirect ownership of 104,525 shares held by the Klein 2024 Revocable Trust (co-trustee), which he disclaims beneficial ownership of except to the extent of pecuniary interest. Vesting schedules apply to the option awards with monthly vesting and IPO-contingent vesting described in footnotes.
Samira Shaikhly, identified as Chief People Officer of Septerna, Inc. (SEPN), acquired a derivative award disclosed on Form 4. The filing reports a grant of a stock option to purchase 30,000 shares of Septerna common stock with an exercise price of $11.70; the transaction date is 08/07/2025 and the Form 4 is signed on 08/11/2025.
The option is owned directly, the instrument lists an expiration date of 08/06/2035, and the grant vests in 1/48th of the shares monthly on each monthly anniversary of August 1, 2025, subject to continuous service. Following the transaction the reporting person beneficially owns 30,000 options.